JP2012523417A5 - - Google Patents

Download PDF

Info

Publication number
JP2012523417A5
JP2012523417A5 JP2012504760A JP2012504760A JP2012523417A5 JP 2012523417 A5 JP2012523417 A5 JP 2012523417A5 JP 2012504760 A JP2012504760 A JP 2012504760A JP 2012504760 A JP2012504760 A JP 2012504760A JP 2012523417 A5 JP2012523417 A5 JP 2012523417A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
lcvr
hcvr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012504760A
Other languages
English (en)
Japanese (ja)
Other versions
JP5759977B2 (ja
JP2012523417A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/030039 external-priority patent/WO2010117980A1/en
Publication of JP2012523417A publication Critical patent/JP2012523417A/ja
Publication of JP2012523417A5 publication Critical patent/JP2012523417A5/ja
Application granted granted Critical
Publication of JP5759977B2 publication Critical patent/JP5759977B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012504760A 2009-04-10 2010-04-06 Ｄｋｋ−１抗体 Active JP5759977B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16841109P 2009-04-10 2009-04-10
US61/168,411 2009-04-10
PCT/US2010/030039 WO2010117980A1 (en) 2009-04-10 2010-04-06 Dkk-1 antibodies

Publications (3)

Publication Number Publication Date
JP2012523417A JP2012523417A (ja) 2012-10-04
JP2012523417A5 true JP2012523417A5 (https=) 2013-05-16
JP5759977B2 JP5759977B2 (ja) 2015-08-05

Family

ID=42199718

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012504760A Active JP5759977B2 (ja) 2009-04-10 2010-04-06 Ｄｋｋ−１抗体

Country Status (30)

Country Link
US (1) US8148498B2 (https=)
EP (3) EP2417158B9 (https=)
JP (1) JP5759977B2 (https=)
KR (3) KR20110124364A (https=)
CN (1) CN102388065B (https=)
AR (1) AR075989A1 (https=)
AU (1) AU2010234611B2 (https=)
BR (1) BRPI1014157B1 (https=)
CA (1) CA2758252C (https=)
CY (3) CY1119399T1 (https=)
DK (3) DK2930184T3 (https=)
EA (1) EA021401B1 (https=)
ES (3) ES2887176T3 (https=)
HR (3) HRP20171400T1 (https=)
HU (3) HUE055376T2 (https=)
IL (1) IL214845A (https=)
LT (3) LT2930184T (https=)
ME (2) ME02798B (https=)
MX (1) MX2011010707A (https=)
NZ (1) NZ595011A (https=)
PL (3) PL2930184T3 (https=)
PT (3) PT2930184T (https=)
RS (3) RS58612B1 (https=)
SG (1) SG175244A1 (https=)
SI (3) SI2930184T1 (https=)
TR (1) TR201907261T4 (https=)
TW (1) TWI546079B (https=)
UA (1) UA103916C2 (https=)
WO (1) WO2010117980A1 (https=)
ZA (1) ZA201107256B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120475A1 (es) 2009-05-12 2012-05-05 Pfizer Anticuerpos especificos para dkk-1
CN111961134B (zh) 2012-12-10 2024-04-05 比奥根Ma公司 抗血液树突细胞抗原2抗体及其用途
AU2016263030A1 (en) * 2015-05-18 2017-10-12 Eli Lilly And Company Anti-Dkk-1-anti-RANKL bispecific antibody compounds
CA2996059A1 (en) * 2015-08-28 2017-03-09 Alector Llc Anti-siglec-7 antibodies and methods of use thereof
EP3370768B9 (en) 2015-11-03 2022-03-16 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
KR102701695B1 (ko) 2016-10-26 2024-08-30 리프 테라퓨틱스 인코포레이티드 항-dkk-1 항체를 사용하여 암을 치료하기 위한 바이오마커로서의 베타-카테닌의 용도
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
MX2020013172A (es) 2018-06-08 2021-03-29 Alector Llc Anticuerpos anti-siglec-7 y sus metodos de uso.
AU2019301160A1 (en) * 2018-07-11 2021-02-25 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered Fc-antigen binding domain constructs targeted to CTLA-4
CN112121147B (zh) * 2019-06-24 2023-07-04 中国人民解放军海军特色医学中心 多肽在治疗或预防骨髓瘤药物中的应用、多肽、核酸、药物及重组表达载体
BR112022004851A2 (pt) * 2019-09-19 2022-08-23 Leap Therapeutics Inc Uso de inibidores de dkk-1 para tratar câncer
EP4061419A1 (en) 2019-11-22 2022-09-28 Leap Therapeutics, Inc. Methods of treating cancer using dkk-1-inhibitors
KR102494042B1 (ko) 2020-11-20 2023-02-07 주식회사 하울바이오 인간모유두세포의 성장을 촉진하는 항-dkk-1 항체 및 이의 용도
CN112592402B (zh) * 2020-12-02 2022-04-26 杭州奕安济世生物药业有限公司 抗dkk2抗体、包含该抗dkk2抗体的组合物及其用途
IL304927A (en) * 2021-02-05 2023-10-01 Omeros Corp A biomarker for assessing the risk of developing acute COVID-19 and post-acute COVID-19
WO2023039249A1 (en) 2021-09-10 2023-03-16 Leap Therapeutics, Inc. Combination therapy
EP4471056A4 (en) * 2022-01-28 2026-02-18 Shanghai Junshi Biosciences Co Ltd Anti-DKK1 antibodies, pharmaceutical composition and associated uses
KR20250057775A (ko) 2022-07-12 2025-04-29 리프 테라퓨틱스 인코포레이티드 조합 요법
CN116589590B (zh) * 2023-03-21 2024-03-26 浙江大学 一种特异性抗异菌脲的单克隆抗体及其重组表达质粒

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU7137398A (en) 1997-04-16 1998-11-11 Millennium Pharmaceuticals, Inc. Crsp protein (cysteine-rich secreted proteins), nucleic acid molecules encoding them and uses therefor
DE19747418C1 (de) * 1997-10-27 1999-07-15 Deutsches Krebsforsch Inhibitor-Protein des wnt-Signalwegs
US7446181B2 (en) * 1998-01-15 2008-11-04 Millennium Pharmaceuticals, Inc. Antibodies that bind human Dickkopf-1 proteins
JP3868740B2 (ja) 1998-03-10 2007-01-17 ジェネンテック・インコーポレーテッド 新規なポリペプチド及びそれをコードする核酸
CA2399776A1 (en) 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
US7736654B2 (en) 2001-04-10 2010-06-15 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
IL158750A0 (en) 2001-05-17 2004-05-12 Genome Therapeutics Corp Reagents and methods for modulating dkk-mediated interactions
US20040038860A1 (en) * 2002-05-17 2004-02-26 Allen Kristina M. Reagents and methods for modulating dkk-mediated interactions
US7371736B2 (en) * 2001-11-07 2008-05-13 The Board Of Trustees Of The University Of Arkansas Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss
US7308364B2 (en) * 2001-11-07 2007-12-11 The University Of Arkansas For Medical Sciences Diagnosis of multiple myeloma on gene expression profiling
JP2005512557A (ja) 2001-11-07 2005-05-12 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ アーカンソー 遺伝子発現プロファイリングに基づく多発性骨髄腫の診断、予後、および治療標的候補の同定
US7642238B2 (en) * 2002-12-05 2010-01-05 Shaughnessy John D Molecular determinants of myeloma bone disease and uses thereof
US20050084494A1 (en) * 2003-05-21 2005-04-21 Darwin Prockop Inhibitors of Dkk-1
EP1636388A2 (en) 2003-06-06 2006-03-22 Wyeth Methods and materials for identifying agents which modulate bone remodeling and agents identified thereby
MX2007001221A (es) 2004-08-04 2007-03-23 Amgen Inc Anticuerpos para proteina dickkopf-1 (dkk-1).
AR060017A1 (es) * 2006-01-13 2008-05-21 Novartis Ag Composiciones y metodos de uso para anticuerpos de dickkopf -1
CN101641373B (zh) * 2007-02-08 2015-02-11 默沙东公司 Dkk-1的特异性抗体
CN102421798A (zh) * 2009-05-07 2012-04-18 诺瓦提斯公司 与dickkopf-1或dickkopf-4或两者的结合分子的组合物及使用方法

Similar Documents

Publication Publication Date Title
JP2012523417A5 (https=)
ME02798B (me) Protutijela protiv dkk-1"
HRP20171992T1 (hr) Protutijela protiv cgrp
JP2013542194A5 (https=)
JP2015514110A5 (https=)
SI3042917T1 (en) Anti-n3pglu amyloid beta peptide antibodies and uses thereof
IL273841B1 (en) Antibodies targeting cd137 and methods of use thereof
JP2020500538A5 (https=)
NZ610294A (en) Human antibodies to human tnf-like ligand 1a (tl1a)
NZ600768A (en) Human antibodies to human angiopoietin-like protein 4
RU2019112029A (ru) Применение комбинации антитела к pd-1 и ингибитора vegfr в изготовлении лекарственного средства для лечения злокачественных новообразований
JP2013529183A5 (https=)
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
HRP20191678T1 (hr) Pd-1 protutijelo, njegov fragment koji se veže na antigen, i njegova medicinska primjena
JP2013542191A5 (https=)
NZ603972A (en) Anti-fgfr2 antibodies
JP2020502198A5 (https=)
JP2023055904A5 (https=)
PE20130226A1 (es) Anticuerpos hacia gdf8 humano
RU2015110981A (ru) Комбинации и их применение
RU2018105846A (ru) Комбинация антагониста pd-1 с ингибитором egfr
JP2015535828A5 (https=)
TN2012000416A1 (en) Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
NZ592436A (en) Treatment with anti-alpha2 integrin antibodies
NZ723369A (en) Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema